TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04877522: An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment

Sponsor: Novartis Pharmaceuticals · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 347 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$443,520

Rescue Site Savings

+$295,680

Unlock Full NCT04877522 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04877522 Rescue Dossier →